HUTCHMED Announces Market Withdrawal of TAZVERIK® in China and Discontinuation of All Clinical Trials

Key Highlights

• HUTCHMED (China) Limited announces the immediate market withdrawal and product recall of TAZVERIK® (tazemetostat) in mainland China, Hong Kong, and Macau.
• The recall follows voluntary withdrawal of TAZVERIK® in the US by Ipsen, the parent company of Epizyme, the developer and marketing authorization holder for TAZVERIK®.
• All active tazemetostat clinical trials, including the SYMPHONY-1 study, are being discontinued due to safety concerns over adverse events, notably secondary hematologic malignancies.
• Existing patients are advised to consult their physicians immediately for alternative treatment options.
• HUTCHMED states the withdrawal is not expected to impact the Company’s financial guidance for 2025, with reported TAZVERIK® sales of US\$2.5 million in 2025.
• HUTCHMED has promptly notified all relevant regulatory and healthcare authorities to cease prescribing and dispensing the product.

Detailed Report

HUTCHMED (China) Limited has announced a major development regarding its licensed oncology product, TAZVERIK® (tazemetostat). As the domestic agent/licensee for Epizyme (an Ipsen company), HUTCHMED has been informed that Ipsen is voluntarily withdrawing TAZVERIK® from the US market. This decision has directly triggered the initiation of a market withdrawal and product recall in the Chinese mainland, Hong Kong, and Macau. All sales and shipments have been suspended, and healthcare professionals, pharmacies, and clinical trial sites have been instructed to discontinue the use and prescription of tazemetostat immediately.

Reason for Withdrawal and Clinical Trial Discontinuation

The withdrawal comes after the Independent Data Monitoring Committee for the Phase Ib/III SYMPHONY-1 trial (which evaluated tazemetostat in combination with lenalidomide plus rituximab for follicular lymphoma) advised that, based on emerging data, the risks of secondary hematologic malignancies may outweigh the potential benefits for patients. In response, Ipsen is halting all tazemetostat treatments, discontinuing all ongoing clinical trials, and stopping expanded access programs worldwide. All participants in the SYMPHONY-1 trial will continue under the standard care of lenalidomide plus rituximab, with no further enrollment. Long-term safety follow-up will continue for current participants.

Regulatory and Market Implications

HUTCHMED has taken swift action to comply with this development, placing the product on hold and immediately notifying the China National Medical Products Administration (NMPA), the Hong Kong Department of Health, and the Macau Health Bureau. The company is actively cooperating with regulatory authorities to ensure a smooth and compliant product recall process.

TAZVERIK® was initially approved by the US FDA in 2020 under the accelerated approval program as a first-in-class methyltransferase inhibitor of EZH2. In China, it received conditional approval from the NMPA for the treatment of follicular lymphoma as an imported drug, with ongoing obligations to report any changes in foreign regulatory status or new safety data. This recall is a direct response to new safety signals, reflecting responsible pharmacovigilance and regulatory compliance.

Financial Impact

The company has assured investors that the withdrawal of TAZVERIK® is not expected to impact its financial guidance for 2025. The product generated sales of US\$2.5 million in 2025, indicating that it was not a major revenue contributor. Nevertheless, the discontinuation of TAZVERIK® could signal increased regulatory scrutiny and a more cautious approach to similar products in the company’s oncology pipeline.

Shareholder Considerations

• The immediate withdrawal of TAZVERIK® may be considered price-sensitive information due to the impact on the company’s product portfolio and clinical development strategy.
• While TAZVERIK® sales have been relatively minor, the discontinuation of all related clinical trials may affect market perception regarding HUTCHMED’s future growth in the oncology segment, especially in combination therapies.
• The company’s prompt disclosure and decisive action may reassure shareholders regarding its commitment to patient safety and regulatory compliance.

Board Statement

The announcement was issued by Non-executive Director and Company Secretary Edith Shih, with a full listing of the current Board of Directors, reflecting the company’s commitment to transparency and corporate governance.

Conclusion

The voluntary recall and discontinuation of TAZVERIK® represent a significant event for HUTCHMED, with potential implications for its clinical pipeline and reputation in the oncology sector. Shareholders should monitor for further updates regarding regulatory outcomes and the company’s strategic response.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on the company’s official announcement and may not cover all aspects of the situation. Investors are encouraged to consult official filings and seek professional advice before making investment decisions.

View HUTCHMED Historical chart here